Business Wire

BIOCORP/ROCHE-DIABETES

Share
BIOCORP Signs Distribution Agreement for Mallya Technology With Roche Diabetes Care France

Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, announces today the signature of a distribution contract for its Mallya connected device with Roche Diabetes Care France.

As part of the agreement, Roche Diabetes Care France will distribute Mallya to pharmacies in France. This medical device is an intelligent 2-year reusable injector pen sensor that is compatible with the majority of insulin injection pens, both disposable and reusable. It automatically collects the insulin dose delivered with near 100% accuracy.

In the future, Mallya will also be part of the RocheDiabetes ecosystem consisting of connected blood glucose meters (Accu-Chek Mobile, Accu-Chek Guide) and digital solutions for better patients care.

Gluci-Chek is a smartphone application regularly used by nearly 60,000 diabetic patients in France. It brings together three major functionalities for personalized diabetes management: a carbohydrate calculation tool with visualization of portions on the plate, a self-monitoring glycemic logbook and a graphic visualization of glycemic results.

Thanks to Mallya, the patient will no longer have to manually report the insulin doses injected in the future since, once the sensor is paired with the Gluci-Chek application, the data will be automatically reported and displayed in the blood glucose monitoring logbook, regardless of the insulin pen1 .

Frédéric Jacquey, President of Roche Diabetes Care France: “The signature of this agreement with Biocorp represents a fundamental step in the development of our ecosystem to improve the care of diabetic patients and their exchanges with healthcare professionals. With innovative technology like Mallya, we will soon be able to offer a unique offering for optimal patient care that integrates blood glucose data from our meters via Gluci-Chek and automatic insulin data via Mallya.”

Éric Dessertenne, CEO of BIOCORP: “Roche is the second pharmaceutical giant to integrate our Mallya connected device for optimal monitoring of diabetic patients into its commercial offer. I would like to thank the teams at Roche Diabetes Care France for their responsiveness over the last few weeks. This new structuring agreement confirms the ambitions presented to all our shareholders in early 2020 on the market of digitalization of diabetes and the considerable commercial potential of Mallya. With a partner of the calibre of Roche, we are confident that a large number of diabetics will quickly be able to benefit from the real benefits offered by Mallya on the secure monitoring of their daily insulin intake."

ABOUT DE ROCHE DIABETES CARE FRANCE
Roche Diabetes Care is a healthcare company specializing in diabetes. For more than 40 years, it has been designing solutions to meet the needs of both patients and healthcare professionals: medical devices (blood glucose meters, lancing devices, insulin pumps), services (information and therapeutic education support) and digital solutions (applications, platform for sharing blood glucose data between patients and healthcare professionals). By creating an ecosystem connecting medical devices and digital solutions, Roche Diabetes Care is paving the way for personalized diabetes management with the aim of facilitating and optimizing the management and monitoring of this complex disease.
Roche Diabetes Care France is a subsidiary of the Roche Group in France, alongside Roche SAS France and Roche Diagnostics France. For more information, please visit www.roche.fr .

ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com .
Follow us on Twitter @BIOCORPSystems

1 SoloStar de Sanofi – KwikPen de Eli Lilly – FlexPen de Novo Nordisk

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aurobay Technologies Expands Digital Transformation Partnership With HCLTech to Boost Manufacturing Excellence and Innovation15.12.2025 14:29:00 CET | Press release

HCLTech, a leading global technology company, and Aurobay Technologies, a division of Horse Powertrain and a global leader in hybrid and low-emission powertrain solutions, have expanded their digital transformation partnership to support Aurobay’s global growth strategy. The expanded partnership establishes HCLTech as Aurobay Technologies’ trusted partner for managing and optimizing SAP, Siemens Teamcenter PLM software and integration services in Sweden and China. This will unlock cost efficiency, operational resilience and digital innovation across Aurobay’s manufacturing and engineering functions by leveraging HCLTech’s flagship service transformation platform, AI Force. The engagement spans core business functions including SAP operations, engineering systems, integration services and mainframe environments, reinforcing Aurobay’s focus on scale, efficiency and seamless operations across global locations. “Horse Powertrain’s division Aurobay Technologies’ digital transformation conti

Applications Now Open for the 5th Cycle of the Mohammed bin Rashid Al Maktoum Global Water Award15.12.2025 14:28:00 CET | Press release

HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE), announced the opening of applications for the 5th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award, offering USD 1 million in prizes. The award seeks to inspire innovative, clean energy–powered solutions for water production, distribution, storage, desalination and purification, supporting global sustainability efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215897854/en/ HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE) - (Photo: AETOSWire) “Since its establishment, Suqia UAE, launched by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has provided clean water to nearly 15 million people in 37 countries worldwide through sustainable development and humanitarian projects.

Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press release

Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au

Ant Group Announces Major Upgrades to Its 15-Million-MAU AI Health App AQ Amid Wider Push into Health Sector15.12.2025 14:03:00 CET | Press release

Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215203213/en/ Ant Group’s AI health app AQ features three core capabilities: health Q&A, AI health companion, and integrated health services. The upgraded version of AQ now features three core capabilities: health Q&A, AI health companion, and integrated health services. Launched in June 2025, AQ has rapidly grown to 15 million monthly active users, making it China’s leading AI health management app. Positioned as an AI health companion service, AQ currently answers over 5 million health-related questions every day. The announcement comes amid China’s ongoing demographic shift. According to projections from the National Health Commission, by around 20

Copeland and Daikin Cooperation Brings Solutions to European Customers15.12.2025 14:00:00 CET | Press release

Strategic collaboration to bring innovative residential solutions designed to reduce emissions and enable sustainable home heating Copeland and Daikin, two global leaders in heating, ventilation and air conditioning (HVAC) solutions, today announced the expansion of their existing joint venture into Europe. Through this cooperation, the companies will introduce advanced inverter swing rotary compressors, power electronics and controls designed specifically for European residential heat pumps. This collaboration underscores both companies’ commitment to accelerate the energy transition, with heat pumps recognized by industry reports as a cornerstone technology helping to reduce global carbon dioxide emissions by an estimated 500 million tons by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215625806/en/ (Left to right) Ross B. Shuster, CEO of Copeland and Jiro Tomita, executive associate officer of Daikin As Europe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye